Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cindella i is an aesthetic injectable product developed by Wells PharmTech, specifically designed for the rejuvenation of the periorbital (eye) area. It is part of the Cindella line, a well-known brand in the South Korean aesthetic market associated with antioxidant and skin-brightening treatments. Cindella i is used to address cosmetic concerns such as dark circles, fine lines, and skin laxity around the eyes. The product typically functions as a skin booster, combining the antioxidant properties of thioctic acid (alpha-lipoic acid) with regenerative components like polydeoxyribonucleotide (PDRN) and hydrating agents like hyaluronic acid to improve skin texture and elasticity. It is administered via superficial injection to promote tissue repair and enhance skin quality in the delicate under-eye region.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cindella i.